CLINICAL HANDBOOK OF SCHIZOPHRENIA

48. The Economics of Schizophrenia 515Haddock, G., Barrowclough, C., Tarrier, N., Moring, J., O’Brien, R., Schofield, N., et al. (2003).Cognitive-behavioral therapy and motivational intervention for schizophrenia and substancemisuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry, 183,418–426.Knapp, M., Mangalore, R., & Simon, J. (2004). The global costs of schizophrenia. Schizophrenia Bulletin,30(2), 279–293.Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al.(2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New EnglandJournal of Medicine, 353(12), 1209–1223.Mark, T., Coffey, R., Vandivort-Warren, R., Harwood, H., & King, E. (2005, January–June). U.S.spending for mental health and substance abuse treatment, 1991–2001. Health Affairs, pp. W5-133–W5-142.National Institute for Health Care Management Research and Educational Foundation. (2002). Prescriptiondrug expenditures in 2001: Another year of escalating costs. Washington, DC: Author.Rice, D. (1999). The economic impact of schizophrenia. Journal of Clinical Psychiatry, 60(Suppl. 1),4–6.Rice, D., & Miller, L. (1996). The economic burden of schizophrenia: Conceptual and methodologicalissues, and cost estimates. In M. Moscarelli, A. Ruff, & N. Sartorius (Eds.), Handbook ofmental health economics and health policy (Vol. 1, pp. 321–334). Chichester, UK: Wiley.Rosenheck, R. (2005). The growth of psychopharmacology in the 1990s: Evidence-based practice orirrational exuberance. International Journal of Law and Psychiatry, 28, 467–483.Voruganti, L. N., Awad, A. G., Oyewumi, L. K., Cortese L., Zirul, S., & Dhawan, R. (2000). Assessinghealth utilities in schizophrenia. Pharmacoeconomics, 17(3), 273–286.